This content is from: Features
How to survive the patent cliff
This year $50 billion worth of drugs come off patent. The pharma industry’s response will be to focus on personalised medicine and biologics. Eileen McDermott explains how this will shift IP strategy towards trade secrets, data and patenting processes
To access our in-house intelligence please request a trial here.
Read this article – and more – for a one-week period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here